Abstract
Amphotericin B, one of the first systemic antifungal agents, has been in use since the past six decades. In light of the recent outbreak of mucormycosis (black fungus) cases during the second coronavirus disease 2019 wave in India, the relevance of knowing the chief aspects of this drug has been renewed. This drug review attempts to revisit the important details available about this agent, which will be of use to the clinician.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
